Published by Josh White on 17th July 2025
(Sharecast News) - IP Group announced on Thursday that its portfolio company Istesso has published peer-reviewed data demonstrating that its new class of oral investigational medicines could promote tissue repair in fibrotic, autoinflammatory, and autoimmune diseases - a first for oral agents in these therapeutic areas.